Association between GvHD and nivolumab in the FDA adverse event reporting system

[1]  Mingfeng Zhang,et al.  PD-L 1 interacts with CD 80 to regulate graft-versus-leukemia activity of donor CD 8 + T cells , 2018 .

[2]  Mingfeng Zhang,et al.  PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells , 2017, The Journal of clinical investigation.

[3]  R. Houot,et al.  Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. , 2017, Blood.

[4]  R. Houot,et al.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. , 2017, Blood.

[5]  S. Stowell,et al.  C3 Modulates RBC Antigen to Negatively Regulate Antibody Response , 2016 .

[6]  P. Hari,et al.  Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease , 2016 .

[7]  Shannon R. McCurdy,et al.  Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide. , 2016 .

[8]  S. Fuji,et al.  Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. , 2016, Stem cell investigation.

[9]  L. Stegger,et al.  Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation , 2016, Bone Marrow Transplantation.

[10]  P. Armand.  Immune checkpoint blockade in hematologic malignancies. , 2015, Blood.

[11]  G. Freeman,et al.  Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. , 2013, Blood.

[12]  A. Panoskaltsis-Mortari,et al.  Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1 , 2003, The Journal of Immunology.